Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) EBITDA: 2010-2016

Historic EBITDA for Tenax Therapeutics (TENX) over the last 3 years, with Dec 2016 value amounting to $33.6 million.

  • Tenax Therapeutics' EBITDA rose 377.52% to $33.6 million in Q4 2016 from the same period last year, while for Dec 2016 it was $31.0 million, marking a year-over-year increase of 137.79%. This contributed to the annual value of -$19.5 million for FY2024, which is 352.82% down from last year.
  • Latest data reveals that Tenax Therapeutics reported EBITDA of $33.6 million as of Q4 2016, which was up 678.79% from $4.3 million recorded in Q3 2016.
  • In the past 5 years, Tenax Therapeutics' EBITDA ranged from a high of $33.6 million in Q4 2016 and a low of -$74.1 million during Q2 2013.
  • Its 2-year average for EBITDA is $7.3 million, with a median of $5.2 million in 2016.
  • Per our database at Business Quant, Tenax Therapeutics' EBITDA tumbled by 3,873.03% in 2013 and then skyrocketed by 377.52% in 2016.
  • Quarterly analysis of 4 years shows Tenax Therapeutics' EBITDA stood at -$682,843 in 2012, then tumbled by 3,873.03% to -$74.1 million in 2013, then reached -$12.1 million in 2015, then spiked by 377.52% to $33.6 million in 2016.
  • Its last three reported values are $33.6 million in Q4 2016, $4.3 million for Q3 2016, and $5.2 million during Q2 2016.